TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 938189

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 30558978

Group type: EXPERIMENTAL
Intervention: Baseline neurocognitive assessment (Brief Assessment of Cognition for Schizophrenia)
Number of subjects: 294
Study: 27544133

Group type: EXPERIMENTAL
Intervention: Laparoscopic-Assisted Combined Hysterectomy (LACH)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Laparoscopic-Assisted Vaginal Hysterectomy (LAVH)
Number of subjects: 101
Study: 26013003

Group type: EXPERIMENTAL
Intervention: PT + active PDT
Number of subjects: 0

Group type: COMPARATOR
Intervention: PT + placebo PDT
Number of subjects: 0
Study: 23671058

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Social skills training (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (MI and Control)
Number of subjects: 40
Study: 22164930

Group type: EXPERIMENTAL
Intervention: Guided group medical art therapy (MAT) for 6 weeks, facilitated by a MAT therapist.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine clinical visit only (Control group B).
Number of subjects: 20
Study: 19809344

Group type: EXPERIMENTAL
Intervention: EP-2104R (4 mumol/kg intravenous bolus injection)
Number of subjects: 52
Study: 16969009

Group type: EXPERIMENTAL
Intervention: Single 0.5 mg ACTH-depot doses for the entire duration of pregnancy
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Series of three 0.5 mg ACTH-depot injections every other day in the first and/or second trimester
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 424
Study: 14748820

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11264604

Group type: EXPERIMENTAL
Intervention: Warm water immersion during labor
Number of subjects: 1237
Study: 9250558

Group type: EXPERIMENTAL
Intervention: Bromfenac 50 mg (3 times/day for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (3 times/day for 3 days)
Number of subjects: 12
Study: 8220804

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg once daily for two weeks
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 3470961

Group type: EXPERIMENTAL
Intervention: PGE1 treatment group (0.2 ng/kg body weight/min and 15,000 I.U. heparin/d for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (3 x 500 mg aspirin and 15,000 I.U. heparin/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGE1 treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30273586

Group type: EXPERIMENTAL
Intervention: 20 mL of extended‐release liposomal bupivacaine (Exparel)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 20 mL of placebo (saline)
Number of subjects: 100
Study: 27925141

Group type: COMPARATOR
Intervention: Traditional renal protective food (control)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Functional food one (FF1)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Functional food two (FF2)
Number of subjects: 81
Study: 24986773

Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30 kg/m²)
Number of subjects: 1924
Study: 22967782

Group type: EXPERIMENTAL
Intervention: Naltrexone induction
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Naltrexone maintenance dose
Number of subjects: 64
Study: 20920764

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 18455480

Group type: EXPERIMENTAL
Intervention: Deep-tissue massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Superficial touch
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study: 15907239

Group type: EXPERIMENTAL
Intervention: Oral Misoprostol (50 microg, 4 hourly to a maximum of four doses)
Number of subjects: 214

Group type: COMPARATOR
Intervention: PGE2 vaginal pessary (at 6 hourly intervals up to two doses)
Number of subjects: 214
Study: 12769340

Group type: EXPERIMENTAL
Intervention: iCNOP (mitoxantrone 20 mg/m2, i.v., d.1)
Number of subjects: 143

Group type: COMPARATOR
Intervention: CHOP (standard regimen)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: iCNOP
Number of subjects: 143

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 143
Study: 10501238

Group type: EXPERIMENTAL
Intervention: CAIV-T
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7485077

Group type: EXPERIMENTAL
Intervention: Loperamide 4 mg po q6h
Number of subjects: 36

Group type: COMPARATOR
Intervention: Octreotide 150 micrograms CI
Number of subjects: 36

Group type: COMPARATOR
Intervention: Octreotide at higher dosage levels (dose escalated to maximum of 2,400 micrograms)
Number of subjects: 36
Study: 1683697

Group type: EXPERIMENTAL
Intervention: Apraclonidine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7345096

Group type: EXPERIMENTAL
Intervention: Counselled group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Uncounselled group (Control)
Number of subjects: 53
Study: 30575093

Group type: EXPERIMENTAL
Intervention: Virtual community (closed Facebook community for peer-to-peer interaction)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Higher adherence to the virtual community
Number of subjects: 121
Study: 28347318

Group type: EXPERIMENTAL
Intervention: Surotomycin 500 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surotomycin 1000 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surotomycin 2000 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surotomycin 4000 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surotomycin 250 mg (MAD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surotomycin 500 mg (MAD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surotomycin 1000 mg (MAD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surotomycin (SAD and MAD)
Number of subjects: 40
Study: 27295864

Group type: COMPARATOR
Intervention: 0.12% CHX mouthrinse
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.2% CHX mouthrinse
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.2% ADS CHX mouthrinse
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.2% CHX
Number of subjects: 60
Study: 24485063

Group type: EXPERIMENTAL
Intervention: Vulnerability-stress intervention
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Biogenetic intervention
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 416
Study: 22621684

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 0
Study: 19432126

Group type: EXPERIMENTAL
Intervention: Combination treatment of active vitamin D3 and alendronate
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Combination treatment of risedronate and vitamin K2
Number of subjects: 2000
Study: 17222256

Group type: EXPERIMENTAL
Intervention: Internet-based virtual microscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional light microscopy
Number of subjects: 0
Study: 15488108

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual therapy (CBT)
Number of subjects: 0
Study: 11159242

Group type: EXPERIMENTAL
Intervention: Levobupivacaine and fentanyl 2 microg/mL
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Levobupivacaine and fentanyl 3 microg/mL
Number of subjects: 106

Group type: COMPARATOR
Intervention: Levobupivacaine control
Number of subjects: 106
Study: 9779700

Group type: EXPERIMENTAL
Intervention: Dexamethasone, high‐dose cytarabine, and cisplatin (DHAP)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Time to relapse
Number of subjects: 188
Study: 7930247

Group type: EXPERIMENTAL
Intervention: Short-stay coronary observation unit
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Comparison patients (admitted to wards, stepdown/intermediate care units, or coronary care unit)
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Comparison patients (discharged home from the emergency department)
Number of subjects: 1516
Study: 3207529

Group type: EXPERIMENTAL
Intervention: 4% amethocaine formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher concentrations of amethocaine (12%) in formulation C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulations A and B (hydrophilic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation C (oil-in-water cream)
Number of subjects: 0
Study: 2119530

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg/day during 1 week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adrenaline infusions (0.1 and 0.4 nmol kg‐1 min‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CWT (colour word conflict test)
Number of subjects: 18
Study: 786348

Group type: EXPERIMENTAL
Intervention: Adrenaline 5 mug/ml added to 1% etidocaine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% etidocaine hydrochloride plain
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% lignocaine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain etidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etidocaine with adrenaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain lignocaine
Number of subjects: 0
Study: 31956998

Group type: EXPERIMENTAL
Intervention: Intensified regimen with rifampin 15 mg/kg and levofloxacin for the first 60 days
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Rifampin 15 mg/kg
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Isoniazid exposure
Number of subjects: 237
Study: 31754048

Group type: EXPERIMENTAL
Intervention: Propranolol (80-160 mg daily for 7 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28385346

Group type: EXPERIMENTAL
Intervention: Early administration of SAP (1.5 g of cefuroxime, intravenous infusion over 2-5 min)
Number of subjects: 5580

Group type: COMPARATOR
Intervention: Late administration of SAP (1.5 g of cefuroxime, intravenous infusion over 2-5 min)
Number of subjects: 5580
Study: 26175059

Group type: EXPERIMENTAL
Intervention: Weight loss through dietary modification and physical activity
Number of subjects: 81
Study: 22966789

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21162469

Group type: EXPERIMENTAL
Intervention: INROADS educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of demographically similar nurses
Number of subjects: 0
Study: 19057207

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate
Number of subjects: 0
Study: 17286624

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (initiated at 300 mg/day, titrated to a maximum of 900 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 0
Study: 15190802

Group type: EXPERIMENTAL
Intervention: Parapost
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Direct post
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Parapost cement
Number of subjects: 90

Group type: COMPARATOR
Intervention: ZPC cement
Number of subjects: 90

Group type: COMPARATOR
Intervention: HY-Bond cement
Number of subjects: 90
Study: 11309009

Group type: COMPARATOR
Intervention: ropivacaine 7.5 mg. ml‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ropivacaine 7.5 mg. ml‐1 + 1 microg. ml‐1 fentanyl
Number of subjects: 30
Study: 9136493

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.1 mg/kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9113119

Group type: EXPERIMENTAL
Intervention: Tropisetron (Navoban)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Dexamethasone plus Metoclopramide
Number of subjects: 115
Study: 3297574

Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (4-ASA) enemas, 1 g bid
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (4-ASA) enemas, 2 g bid
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 4-ASA in open-label trial
Number of subjects: 47
Study: 31411975

Group type: EXPERIMENTAL
Intervention: PSA >40ng/ml, GGG5, and GGG4
Number of subjects: 201224

Group type: EXPERIMENTAL
Intervention: PSA, clinical tumor stage, and GGG
Number of subjects: 201224

Group type: EXPERIMENTAL
Intervention: Calibration plot
Number of subjects: 201224

Group type: EXPERIMENTAL
Intervention: Decision curve analysis (DCA)
Number of subjects: 201224
Study: 29550184

Group type: EXPERIMENTAL
Intervention: Surgeon's assessment of residual disease (RD)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Pre-treatment computed tomography (CT) findings
Number of subjects: 627
Study: 28089187

Group type: EXPERIMENTAL
Intervention: Multimodal cocktail injection with morphine (10 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Multimodal cocktail injection without morphine
Number of subjects: 102
Study: 26018036

Group type: EXPERIMENTAL
Intervention: Nasal mupirocin (Bactroban) twice daily and hexachlorophene (pHIsoHex) soaps daily for 7 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo similar in appearance but without specific antibacterial activity
Number of subjects: 49
Study: 23812521

Group type: EXPERIMENTAL
Intervention: Intravitreal injection (PRPplus group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP group)
Number of subjects: 31
Study: 21489866

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Eyes-open condition
Number of subjects: 22

Group type: COMPARATOR
Intervention: Eyes-closed placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Eyes-open caffeine
Number of subjects: 22
Study: 20025753

Group type: EXPERIMENTAL
Intervention: Surface-based deformable image registration (DR)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No deformable image registration (Control)
Number of subjects: 13
Study: 17020801

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate surgical sealant
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control (oxidized cellulose)
Number of subjects: 151
Study: 12757447

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 9890611

Group type: EXPERIMENTAL
Intervention: Preterm newborns (mean 4.6+/‐6.9 ng/mL)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Term newborns (mean 19.6+/‐14.3 ng/mL)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Newborns at approximately 6 days of life (mean 1.9+/‐1.1 ng/mL)
Number of subjects: 326
Study: 8915402

Group type: EXPERIMENTAL
Intervention: Taurine powder (6 g/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 22
Study: 1853148

Group type: COMPARATOR
Intervention: Cimetidine, 400 mg twice a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g four times a day
Number of subjects: 60
Study: 6421002

Group type: EXPERIMENTAL
Intervention: Gallopamil (D 600) 50 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gallopamil (D 600) 150 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30185146

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 50
Study: 27352907

Group type: EXPERIMENTAL
Intervention: Patch tests including baseline series plus selected allergens
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prick tests including standard inhalational allergens plus natural rubber latex and chlorhexidine
Number of subjects: 120
Study: 24975596

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 353

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 353
Study: 23579360

Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 = 0.3)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 8
Study: 20537406

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Motivation enhancement therapy (MET)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Reduction in anxiety from baseline to 4-month follow-up
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Baseline anxiety
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Reduction in marijuana use
Number of subjects: 450
Study: 18467543

Group type: EXPERIMENTAL
Intervention: CHO + Caff (8 mg/kg BM)
Number of subjects: 7

Group type: COMPARATOR
Intervention: CHO (4 g/kg body mass)
Number of subjects: 7
Study: 15685961

Group type: EXPERIMENTAL
Intervention: Negative framing
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Positive framing
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Life-death scenario
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Public property (paintings)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Personal property (money)
Number of subjects: 384
Study: 15305841

Group type: EXPERIMENTAL
Intervention: Intracerebral microdialysis and bedside biochemical analyses for monitoring cerebral energy metabolism.
Number of subjects: 0
Study: 10451911

Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7598280

Group type: EXPERIMENTAL
Intervention: Milrinone (loading dose of 50-75 micrograms/kg followed by 0.5-0.75 micrograms.kg-1.min-1 for 12-24 h)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No milrinone (control group, n = 10)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 27
Study: 2130425

Group type: EXPERIMENTAL
Intervention: Hidrosmin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diosmin
Number of subjects: 20
Study: 368975

Group type: EXPERIMENTAL
Intervention: High doses of vitamin B6 (pyridoxine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 31065844

Group type: EXPERIMENTAL
Intervention: Protein intake ≥ 1.1 g/kg BW
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Higher tertile of animal protein intake
Number of subjects: 440

Group type: COMPARATOR
Intervention: Protein intake < 1.1 g/kg BW
Number of subjects: 440
Study: 30933748

Group type: EXPERIMENTAL
Intervention: Individually delivered treatment
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Trauma-focused treatments
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: History of traumatic brain injury (TBI)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Patients who did not drop out
Number of subjects: 557
Study: 29237915

Group type: EXPERIMENTAL
Intervention: Auricular points treatment combined with acupoints application therapy
Number of subjects: 341

Group type: COMPARATOR
Intervention: Routine nursing care (control group)
Number of subjects: 341
Study: 25759456

Group type: EXPERIMENTAL
Intervention: Mobile phone text messages (SMS) sent to LCS over an 8-week period
Number of subjects: 0
Study: 22871333

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg once-daily, individualized within 400-1200 mg range
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 325
Study: 21361810

Group type: EXPERIMENTAL
Intervention: Multidisciplinary hygiene intervention
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Multidisciplinary hygiene intervention (secular preschools only)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Multidisciplinary hygiene intervention (secular preschools)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Multidisciplinary hygiene intervention (religious preschools)
Number of subjects: 1029
Study: 19701676

Group type: EXPERIMENTAL
Intervention: Rasburicase 0.15 mg/kg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rasburicase 0.20 mg/kg/day
Number of subjects: 30
Study: 16628242

Group type: EXPERIMENTAL
Intervention: Luneau SA applanator
Number of subjects: 79

Group type: COMPARATOR
Intervention: Goldmann applanator
Number of subjects: 79
Study: 15166654

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (beer, 40g/day for men, 30g/day for women)
Number of subjects: 19
Study: 11201510

Group type: EXPERIMENTAL
Intervention: Isoflavone-rich soy protein (80.4 mg/day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Isoflavone-poor soy protein (4.4 mg/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Whey protein control
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 69
Study: 9832603

Group type: EXPERIMENTAL
Intervention: Active Eating (AE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Passive Eating (PE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control periods during AE
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control periods during PE
Number of subjects: 35
Study: 8728680

Group type: EXPERIMENTAL
Intervention: Endoscopic pyeloplasty with endoscopic suturing of the incised UPJ
Number of subjects: 8

Group type: COMPARATOR
Intervention: Endopyelotomy (standard method)
Number of subjects: 8
Study: 2156647

Group type: EXPERIMENTAL
Intervention: High glucose intake (105 kJ/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low glucose intake (30 kJ/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High nitrogen intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Added glucose intake
Number of subjects: 12